[go: up one dir, main page]

WO2002034776A3 - Epitopes de pai-1 - Google Patents

Epitopes de pai-1 Download PDF

Info

Publication number
WO2002034776A3
WO2002034776A3 PCT/BE2001/000186 BE0100186W WO0234776A3 WO 2002034776 A3 WO2002034776 A3 WO 2002034776A3 BE 0100186 W BE0100186 W BE 0100186W WO 0234776 A3 WO0234776 A3 WO 0234776A3
Authority
WO
WIPO (PCT)
Prior art keywords
pai
substances
peptides
proteins
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BE2001/000186
Other languages
English (en)
Other versions
WO2002034776A2 (fr
Inventor
Paul Declerck
Jean-Marie Stassen
Ann-Pascal Bijnens
Ann Gils
Thu Hoa Ngo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000153251 external-priority patent/DE10053251A1/de
Priority claimed from DE2001110235 external-priority patent/DE10110235A1/de
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Priority to AU2002216847A priority Critical patent/AU2002216847A1/en
Publication of WO2002034776A2 publication Critical patent/WO2002034776A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002034776A3 publication Critical patent/WO2002034776A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne le domaine des maladies cardiovasculaires et thromboemboliques et des cancers et maladies associée. L'invention concerne des protéines, des peptides comportant des épitopes spécifiés de l'inhibiteur de type 1 de l'activateur du plasminogène (PAI-1), et des acides nucléiques codant ces protéines ou peptides. L'invention traite également de méthodes de criblage de substances pouvant inhiber ledit PAI-1, de substances pouvant être identifiées au moyen de ladite méthode et de compositions pharmaceutiques comportant lesdites substances.
PCT/BE2001/000186 2000-10-26 2001-10-25 Epitopes de pai-1 Ceased WO2002034776A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002216847A AU2002216847A1 (en) 2000-10-26 2001-10-25 Epitopes of pai-1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10053251.9 2000-10-26
DE2000153251 DE10053251A1 (de) 2000-10-26 2000-10-26 Epitope von PAI-1
DE2001110235 DE10110235A1 (de) 2001-03-02 2001-03-02 Epitope von PAI-1
DE10110235.6 2001-03-02

Publications (2)

Publication Number Publication Date
WO2002034776A2 WO2002034776A2 (fr) 2002-05-02
WO2002034776A3 true WO2002034776A3 (fr) 2004-01-08

Family

ID=26007505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2001/000186 Ceased WO2002034776A2 (fr) 2000-10-26 2001-10-25 Epitopes de pai-1

Country Status (2)

Country Link
AU (1) AU2002216847A1 (fr)
WO (1) WO2002034776A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
CA2366682C (fr) 1999-04-09 2009-06-23 Rigshospitalet Inhibiteur tissulaire de metalloproteinases matricielles type-1 (timp-1) comme marqueur de cancer
GB0405033D0 (en) * 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
WO2005094863A1 (fr) * 2004-03-30 2005-10-13 Den Kgl.Veterinær-Og Landbohøjskole Ameliorations dans le traitement du cancer et prediction efficace de traitement du cancer par le blocage et la detection d'inhibiteurs de la protease
RU2301678C1 (ru) 2006-05-30 2007-06-27 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Пептид, стимулирующий регенерацию нейронов центральной нервной системы, фармацевтическая композиция на его основе и способ ее применения
AU2008278568B2 (en) * 2007-07-24 2013-08-01 D-Pharm Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
CN105705520B (zh) * 2013-08-13 2020-09-25 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
MX2016010852A (es) * 2014-02-21 2016-10-26 Astellas Pharma Inc Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020295A1 (fr) * 1997-10-17 1999-04-29 Trustees Of The University Of Pennsylvania Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020295A1 (fr) * 1997-10-17 1999-04-29 Trustees Of The University Of Pennsylvania Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIJNENS A P ET AL: "Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1.", THROMBOSIS AND HAEMOSTASIS, vol. 85, no. 5, May 2001 (2001-05-01), pages 866 - 874, XP008009142, ISSN: 0340-6245 *
BIJNENS ANN-PASCALE ET AL: "The distal hinge of the reactive site loop and its proximity. A target to modulate plasminogen activator inhibitor-1 activity.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 48, 30 November 2001 (2001-11-30), November 30, 2001, pages 44912 - 44918, XP002217300, ISSN: 0021-9258 *
BJORQUIST PETTER ET AL: "Epitopes on plasminogen activator inhibitor type-1 important of binding to tissue plasminogen activator.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1341, no. 1, 1997, pages 87 - 98, XP002217299, ISSN: 0006-3002 *
DEBROCK SOPHIE ET AL: "Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1337, no. 2, 1997, pages 257 - 266, XP002216855, ISSN: 0006-3002 *
FRANDSEN THOMAS L ET AL: "Blocking PAI-1 function inhibits metastasis formation from a human breast cancer xenograft in nude mice.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 452, XP008009141, ISSN: 0197-016X *
PANNEKOEK H ET AL: "ENDOTHELIAL PLASMINOGEN ACTIVATOR INHIBITOR A NEW MEMBER OF THE SERPIN GENE FAMILY", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 5, no. 10, 1986, pages 2539 - 2544, XP008009461, ISSN: 0261-4189 *
VLEUGELS N ET AL: "Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant.", FIBRINOLYSIS & PROTEOLYSIS, vol. 12, no. 5, 1998, pages 277 - 282, XP008009134, ISSN: 1369-0191 *

Also Published As

Publication number Publication date
WO2002034776A2 (fr) 2002-05-02
AU2002216847A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
AU2002305450A1 (en) Proteomimetic compounds and methods
HUP0300148A3 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
MXPA03005219A (es) Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
WO2002008256A3 (fr) Nouveaux peptides utilises comme inhibiteurs de serine ns3 protease du virus de l'hepatite c
AU2001277967A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2002008244A3 (fr) Nouveau peptide sous forme d'inhibiteurs de protease a serine ns3 d'hepatite virale c
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
WO1997033996A3 (fr) Bikunine humaine
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
AU1453200A (en) Cyclic peptide ligands that target urokinase plasminogen activator receptor, their pharmaceutical compositions and use
WO2002066653A3 (fr) Banques procaryotiques et leurs utilisations
WO2002014485A3 (fr) Nouveau gene kallikreine
WO2002034776A3 (fr) Epitopes de pai-1
WO2002060917A3 (fr) Methode de traitement de l'hemophilie
AU2001238212A1 (en) Modified fluorescent proteins
WO2002068476A3 (fr) Composition et procede de traitement de troubles inflammatoires
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
WO2002049625A3 (fr) Composés affectant l'expression de cd83, compositions pharmaceutiques à base de telles composés, et procédés permettant d'identifier ces composés
WO2002034915A3 (fr) Segments preferes de la proteine neurale ntp et ses procedes d'utilisation
AU2003247537A1 (en) Chd5 encoding nucleic acids, polypeptides, antibodies and methods of use thereof
WO2005037236A3 (fr) Nouveaux polypeptides associes a la proteine de choc thermique 20 et utilisations
SG161106A1 (en) Inhibitor proteins of a protease and use thereof
WO2003010184A3 (fr) Motif conserve d'interaction de xiap dans la caspase-9 et la proteine smac/diablo pour moduler l'apoptose
WO2001068846A3 (fr) Proteine transactivatrice transcriptionnelle

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP